Crossmark

NKT cell-dependent glycolipid–peptide vaccines with potent anti-tumour activity

Crossref DOI link: https://doi.org/10.1039/c4sc03599b

Published Online: 2015

Update policy: https://doi.org/10.1039/rsc_crossmark_policy

Authors

Anderson, Regan J. https://orcid.org/0000-0003-3467-9202
Compton, Benjamin J. https://orcid.org/0000-0002-5245-9767
Tang, Ching-wen

Authier-Hall, Astrid

Hayman, Colin M.

Swinerd, Gene W.

Kowalczyk, Renata

Harris, Paul

Brimble, Margaret A.

Larsen, David S.

Gasser, Olivier

Weinkove, Robert https://orcid.org/0000-0003-3645-7988
Hermans, Ian F.

Painter, Gavin F. https://orcid.org/0000-0002-1310-7769
Funding

Funding for this research was provided by:

Genesis Oncology Trust (GOT-1352-RPG)

Ministry of Science and Innovation, New Zealand (C08X0808)

Health Research Council of New Zealand (14-500)
More Information

SIMILARITY CHECK

: This document is Similarity Check deposited

RELATED DATA

: Supplementary Information

IDENTIFIERS

: Regan J. Anderson (ORCID)

: Benjamin J. Compton (ORCID)

: Robert Weinkove (ORCID)

: Robert Weinkove (ResearcherID)

: Gavin F. Painter (ORCID)

COPYRIGHT AND LICENSING

: The Royal Society of Chemistry has an exclusive publication licence for this journal

OPEN ACCESS: This article is freely available. This article is licensed under a Creative Commons Attribution Non Commercial 3.0 Unported Licence (CC BY-NC 3.0)

PEER REVIEW METHOD

: Single-blind

PUBLICATION HISTORY

: Received 20 November 2014; Accepted 25 June 2015; Accepted Manuscript published 25 June 2015; Advance Article published 9 July 2015; Version of Record published 10 August 2015